NGM Biopharmaceuticals Inc.

05/12/2022 | Press release | Distributed by Public on 05/12/2022 06:04

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors